Processa Pharmaceuticals is acquiring Vidya Therapeutics in an all-stock deal that gives it a clinical-stage oral BTK inhibitor and sets up a future challenge to a newly approved Novartis drug.
Announced July 29, 2026 and expected to close July 31, the transaction centers on VT-7208, an oral, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK) — an enzyme that helps drive immune-cell activity behind many inflammatory and allergic conditions. Alongside the deal, Processa is raising $200 million in a concurrent private placement, a substantial cushion for a company that reported just $1.7 million in cash at the end of the first quarter. Management says the financing extends its runway into the second half of 2029.
What makes VT-7208 different
Processa is positioning VT-7208 as a differentiated, next-generation BTK inhibitor: once-daily dosing, brain-penetrating properties, and a design intended to minimize off-target effects that can raise the risk of liver complications. The company plans to test it across food allergy, chronic spontaneous urticaria (CSU), relapsing multiple sclerosis, and rare inflammatory skin disorders such as hidradenitis suppurativa and chronic inducible urticaria.
The Novartis comparison
The obvious benchmark is Novartis’s Rhapsido (remibrutinib), the first BTK inhibitor approved for an immunological indication, cleared in October 2025 for chronic spontaneous urticaria. Rhapsido is dosed twice daily; Processa is betting a once-daily, brain-penetrating profile could carve out room in a fast-emerging class.
What comes next
Processa laid out an ambitious clinical calendar: Phase 2 studies in food allergy and CSU are slated to begin in the second half of 2026, with food-allergy data expected in the second half of 2027 and CSU data in the first half of 2028. A Phase 2 multiple sclerosis study is planned for the first half of 2027, with data in the second half of 2028. As with any early pipeline, those readouts — not the deal itself — will decide whether the bet pays off.